Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

被引：0
|
作者：
Yongliang Feng
Jing Chen
Tian Yao
Yue Chang
Xiaoqing Li
Rongqin Xing
Hong Li
Ruixue Xie
Xiaohong Zhang
Zhiyun Wei
Shengcai Mu
Ling Liu
Lizhong Feng
Suping Wang
机构：
[1] Shanxi Medical University,Department of Epidemiology, School of Public Health
[2] Shanxi Medical University,Center of Clinical Epidemiology and Evidence Based Medicine
[3] Shanxi Provincial Center for Disease Control and Prevention,undefined
[4] Shanxi Provincial Key Laboratory for Major Infectious Disease Response,undefined
[5] Outpatient Department of Shanxi Aviation Industry Group Co. LTD,undefined
来源：
Infectious Diseases of Poverty | / 10卷
关键词：
COVID-19; Inactivated SARS-CoV-2 vaccine; Immunogenicity; Safety; High-risk occupational population; Randomized controlled trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
    Han, Bihua
    Song, Yufei
    Li, Changgui
    Yang, Wanqi
    Ma, Qingxia
    Jiang, Zhiwei
    Li, Minjie
    Lian, Xiaojuan
    Jiao, Wenbin
    Wang, Lei
    Shu, Qun
    Wu, Zhiwei
    Zhao, Yuliang
    Li, Qi
    Gao, Qiang
    LANCET INFECTIOUS DISEASES, 2021, 21 (12): : 1645 - 1653
  • [22] Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents
    Kamei, Koichi
    Ogura, Masao
    Sato, Mai
    Nishi, Kentaro
    Shoji, Kensuke
    Funaki, Takanori
    Ogimi, Chikara
    Ito, Shuichi
    PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [23] Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial
    Mostafavi, Ehsan
    Eybpoosh, Sana
    Karamouzian, Mohammad
    Khalili, Malahat
    Haji-Maghsoudi, Saiedeh
    Salehi-Vaziri, Mostafa
    Khamesipour, Ali
    Jalali, Tahmineh
    Nakhaeizadeh, Mehran
    Sharifi, Hamid
    Mansoori, Yasaman
    Keramat, Fariba
    Ghodrati, Samad
    Javanian, Mostafa
    Doroud, Delaram
    Omrani, Mir Davood
    Asadi, Hassan
    Pouriayevali, Mohammad Hassan
    Ghasemian, Roya
    Farshidi, Hossein
    Pourahmad, Morteza
    Ghasemzadeh, Iman
    Mounesan, Leila
    Darvishian, Maryam
    Mirjalili, Mohamad Reza
    Toledo-Romani, Maria Eugenia
    Valenzuela-Silva, Carmen
    Verez-Bencomo, Vicente
    Gouya, Mohammad Mehdi
    Emadi-Koochak, Hamid
    Haghdoost, Ali Akbar
    Biglari, Alireza
    JAMA NETWORK OPEN, 2023, 6 (05)
  • [24] Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
    Zeng, Guangting
    LANCET MICROBE, 2022, 3 (08): : E561 - E561
  • [25] Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial
    Abarca, Katia
    Iturriaga, Carolina
    Urzua, Marcela
    Le Corre, Nicole
    Pineda, Augusto
    Fernandez, Carolina
    Dominguez, Angelica
    Gonzalez, Pablo A.
    Bueno, Susan M.
    Donato, Paulina
    Espinoza, Pilar
    Fuentes, Daniela
    Gonzalez, Marcela
    Guzman, Paula
    Munoz-Venturelli, Paula
    Perez, Carlos M.
    Potin, Marcela
    Rojas, Alvaro
    Gonzalez-Aramundiz, Jose, V
    Galvez, Nicolas M. S.
    Aguirre-Boza, Francisca
    Aljaro, Sofia
    Federico Batiz, Luis
    Campisto, Yessica
    Cepeda, Mariela
    Cortes, Aaron
    Lopez, Sofia
    Loreto Perez, Maria
    Schilling, Andrea
    Kalergis, Alexis M.
    VACCINES, 2022, 10 (07)
  • [26] Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection
    Xiang, Tiandan
    Liang, Boyun
    Wang, Hua
    Quan, Xufeng
    He, Shengsong
    Zhou, Helong
    He, Yongwen
    Yang, Dongliang
    Wang, Baoju
    Zheng, Xin
    CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (12) : 2679 - 2681
  • [27] Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection
    Tiandan Xiang
    Boyun Liang
    Hua Wang
    Xufeng Quan
    Shengsong He
    Helong Zhou
    Yongwen He
    Dongliang Yang
    Baoju Wang
    Xin Zheng
    Cellular & Molecular Immunology, 2021, 18 : 2679 - 2681
  • [28] Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
    Medeiros-Ribeiro, Ana
    Aikawa, Nadia
    Schahin Saad, Carla Goncalves
    Vieira Neves Yuki, Emily Figueiredo
    Pedrosa, Tatiana do Nascimento
    Fusco, Solange
    Rojo, Priscila
    Pereira, Rosa
    Shinjo, Samuel
    Andrade, Danieli
    Sampaio-Barros, Percival
    Ribeiro, Carolina
    Deveza, Giordano
    de Oliveira Martins, Victor Adriano
    Silva, Clovis Artur
    Lopes, Marta
    Duarte, Alberto
    Antonangelo, Leila
    Sabino, Ester
    Kallas, Esper
    Pasoto, Sandra Gofinet
    Bonfa, Eloisa
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3260 - 3263
  • [29] Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial
    Thiem, Vu Dinh
    Anh, Dang Duc
    Ha, Vu Hai
    Thom, Nguyen Van
    Thang, Tran Cong
    Mateus, Jose
    Carreno, Juan Manuel
    Raghunandan, Rama
    Huong, Nguyen Mai
    Mercer, Laina D.
    Flores, Jorge
    Escarrega, E. Alexandar
    Raskin, Ariel
    Thai, Duong Huu
    Be, Le Van
    Sette, Alessandro
    Innis, Bruce L.
    Krammer, Florian
    Weiskopf, Daniela
    VACCINE, 2025, 44
  • [30] Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 A phase 1 randomized clinical trial
    Kremsner, Peter G.
    Mann, Philipp
    Kroidl, Arne
    Leroux-Roels, Isabel
    Schindler, Christoph
    Gabor, Julian J.
    Schunk, Mirjam
    Leroux-Roels, Geert
    Bosch, Jacobus J.
    Fendel, Rolf
    Kreidenweiss, Andrea
    Velavan, Thirumalaisamy P.
    Fotin-Mleczek, Mariola
    Mueller, Stefan O.
    Quintini, Gianluca
    Schoenborn-Kellenberger, Oliver
    Vahrenhorst, Dominik
    Verstraeten, Thomas
    de Mesquita, Margarida Alves
    Walz, Lisa
    Wolz, Olaf-Oliver
    Oostvogels, Lidia
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (17-18) : 931 - 941
12345